Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.
Kazansky Y, Mueller HS, Cameron D, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Mundi PS, Kuwahara Y, Somwar R, Qu R, Califano A, de Stanchina E, Dela Cruz FS, Kung AL, Gounder MM, Kentsis A. Kazansky Y, et al. Among authors: zuco v. bioRxiv [Preprint]. 2024 May 6:2024.05.03.592420. doi: 10.1101/2024.05.03.592420. bioRxiv. 2024. PMID: 38766189 Free PMC article. Preprint.
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy.
Kazansky Y, Cameron D, Mueller HS, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Kuwahara Y, Somwar R, Ladanyi M, Qu R, De Stanchina E, Dela Cruz FS, Kung AL, Gounder M, Kentsis A. Kazansky Y, et al. Among authors: zuco v. bioRxiv [Preprint]. 2023 Dec 1:2023.02.06.527192. doi: 10.1101/2023.02.06.527192. bioRxiv. 2023. Update in: Cancer Discov. 2024 Jun 3;14(6):965-981. doi: 10.1158/2159-8290.CD-23-0110 PMID: 36798379 Free PMC article. Updated. Preprint.
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression.
Stacchiotti S, Martini S, Pasquali S, Frezza AM, Beretta A, Percio S, Lecchi M, Tortoreto M, Barisella M, Collini P, Dagrada GP, Merlini A, Huang PH, Jenks A, Jones RL, Tap WD, Ingrosso M, Morosi C, Brich S, Giani C, Verderio P, Casali PG, Leonard H, Gronchi A, Zuco V, Zaffaroni N. Stacchiotti S, et al. Among authors: zuco v. Clin Cancer Res. 2024 Nov 15;30(22):5122-5137. doi: 10.1158/1078-0432.CCR-23-3991. Clin Cancer Res. 2024. PMID: 39283723 Free PMC article.
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
Kazansky Y, Cameron D, Mueller HS, Demarest P, Zaffaroni N, Arrighetti N, Zuco V, Kuwahara Y, Somwar R, Ladanyi M, Qu R, de Stanchina E, Dela Cruz FS, Kung AL, Gounder MM, Kentsis A. Kazansky Y, et al. Among authors: zuco v. Cancer Discov. 2024 Jun 3;14(6):965-981. doi: 10.1158/2159-8290.CD-23-0110. Cancer Discov. 2024. PMID: 38315003 Free PMC article.
Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft.
Zuco V, Pasquali S, Tortoreto M, Percio S, Doldi V, Barisella M, Collini P, Dagrada GP, Brich S, Gasparini P, Fiore M, Casanova M, Frezza AM, Gronchi A, Stacchiotti S, Ferrari A, Zaffaroni N. Zuco V, et al. Dis Model Mech. 2023 Jun 1;16(6):dmm049649. doi: 10.1242/dmm.049649. Epub 2023 Jun 14. Dis Model Mech. 2023. PMID: 37158111 Free PMC article.
Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma.
Alessandrini I, Percio S, Naghshineh E, Zuco V, Stacchiotti S, Gronchi A, Pasquali S, Zaffaroni N, Folini M. Alessandrini I, et al. Among authors: zuco v. Cancers (Basel). 2022 May 25;14(11):2624. doi: 10.3390/cancers14112624. Cancers (Basel). 2022. PMID: 35681604 Free PMC article.
miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.
El Bezawy R, Percio S, Ciniselli CM, De Cesare M, Colella G, Dugo M, Veneroni S, Doldi V, Martini S, Baratti D, Kusamura S, Verderio P, Deraco M, Gandellini P, Zaffaroni N, Zuco V. El Bezawy R, et al. Among authors: zuco v. Cancer Gene Ther. 2022 Oct;29(10):1394-1404. doi: 10.1038/s41417-022-00460-7. Epub 2022 Mar 29. Cancer Gene Ther. 2022. PMID: 35352023 Free PMC article.
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.
Antoniotti C, Marmorino F, Boccaccino A, Martini S, Antista M, Rossini D, Zuco V, Prisciandaro M, Conca V, Zucchelli G, Borelli B, Cosentino P, Germani MM, Bosco MF, Carullo M, Vetere G, Moretto R, Giordano M, Masi G, Pietrantonio F, Zaffaroni N, Cremolini C. Antoniotti C, et al. Among authors: zuco v. Eur J Cancer. 2022 Apr;165:116-124. doi: 10.1016/j.ejca.2022.01.025. Epub 2022 Feb 26. Eur J Cancer. 2022. PMID: 35231767
75 results